Cellectis expects interim readout in Q4 2026 from pivotal BALLI-01 trial of lasme-cel in relapsed/refractory B-cell ALL
CLLS•Eti-cel continues in Phase 1 lymphoma study
The company also advanced eti-cel in an ongoing Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma.
Translational findings were presented at EHA 2026; the full Phase 1 clinical dataset is expected in Q4 2026.
Lasme-cel advances in pivotal Phase 2 study
Cellectis highlighted progress on lasme-cel, now in a pivotal Phase 2 study in relapsed or refractory B-cell acute lymphoblastic leukemia.
Full Phase 1 results were presented at the 2026 European Hematology Association meeting, supporting continued development based on encouraging responses and manageable safety.
An interim readout from the pivotal Phase 2 study is scheduled for Q4 2026, a key catalyst for regulatory strategy.
